Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

NCT06880419 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

174

Enrollment

OTHER

Sponsor class

Conditions

Acute Graft-versus-Host Disease

Interventions

DRUG: Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection

Sponsor

Institute of Hematology & Blood Diseases Hospital, China